Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer

Speaking of SurgOnc

Annals of Surgical Oncology and Society of Surgical Oncology, Annals of Surgical Oncology, and Society of Surgical Oncology द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री Annals of Surgical Oncology and Society of Surgical Oncology, Annals of Surgical Oncology, and Society of Surgical Oncology या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal।

2+ y ago 11:42

MP3•एपिसोड होम

Rick Greene, MD, and Mark Truty, MD, discuss the role of neoadjuvant chemotherapy in the treatment of pancreatic cancer, including the optimal treatment of patients who do not respond to first-line chemotherapy or develop toxicities. Dr. Truty is author of, “Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer.” Dr. Truty is Associate Professor of Surgery, Mayo Clinic, Rochester, MN, where his clinical practice is in the Division of Subspecialty General Surgery, Department of Surgery.

61 एपिसोडस

#Science #Annals of Surgical Oncology and Society of Surgical Oncology #Research #Globalcancersurgery #Surgicaloncology #Annals Of Surgical Oncology #Society Of Surgical Oncology #Podcasting Education